Analysis of Campylobacter glycan-recognizing antibodies related to Guillain-Barre syndrome in human serum

Analysis of Campylobacter cell wall glycan-recognizing antibodies associated with the pathogenesis of Guillain-Barre syndrome in human serum - GBS-Campy Ab study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061349

Enrollment

150

Registered

2026-05-01

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Guillain-Barre syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with a confirmed diagnosis of Guillain-Barre syndrome (GBS) Patients suspected of Guillain-Barre syndrome Neurology outpatients without GBS

Exclusion criteria

Exclusion criteria: Individuals who do not provide informed consent to participate in the study Individuals from whom adequate serum samples cannot be obtained or whose samples are of insufficient quality Individuals who are receiving immunosuppressive therapy (e.g., high-dose corticosteroids or immunosuppressive agents) that may affect antibody measurements, as judged by the principal investigator Individuals deemed inappropriate for inclusion in the study by the principal investigator for any other reason

Design outcomes

Primary

Measure	Time frame
Prevalence of anti-ganglioside antibodies Prevalence of anti-Campylobacter LOS antibodies Comparison between GBS patients and non-GBS outpatient controls	—

Countries

Japan

Contacts

Public ContactShimizu Takeshi

Chiba University Graduate School of Medicine

tshimizu@faculty.chiba-u.jp043-226-2048

Outcome results